TCRX Valuation
TScan Therapeutics Inc
$
1.740
- Overview
- Forecast
- Valuation
- Earnings
TCRX Relative Valuation
TCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TCRX is overvalued; if below, it's undervalued.
Historical Valuation
TScan Therapeutics Inc (TCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 15.66 is considered Undervalued compared with the five-year average of -2.57. The fair price of TScan Therapeutics Inc (TCRX) is between 2.52 to 5.03 according to relative valuation methord. Compared to the current price of 1.70 USD , TScan Therapeutics Inc is Undervalued By 32.59%.
Relative Value
Fair Zone
2.52-5.03
Current Price：1.70
32.59%
Undervalued
-1.35
PE
1Y
3Y
5Y
Trailing
Forward
0.17
EV/EBITDA
TScan Therapeutics Inc. (TCRX) has a current EV/EBITDA of 0.17. The 5-year average EV/EBITDA is -0.54. The thresholds are as follows: Strongly Undervalued below -3.65, Undervalued between -3.65 and -2.09, Fairly Valued between 1.02 and -2.09, Overvalued between 1.02 and 2.58, and Strongly Overvalued above 2.58. The current Forward EV/EBITDA of 0.17 falls within the Historic Trend Line -Fairly Valued range.
0.16
EV/EBIT
TScan Therapeutics Inc. (TCRX) has a current EV/EBIT of 0.16. The 5-year average EV/EBIT is -0.49. The thresholds are as follows: Strongly Undervalued below -3.52, Undervalued between -3.52 and -2.01, Fairly Valued between 1.02 and -2.01, Overvalued between 1.02 and 2.54, and Strongly Overvalued above 2.54. The current Forward EV/EBIT of 0.16 falls within the Historic Trend Line -Fairly Valued range.
14.70
PS
TScan Therapeutics Inc. (TCRX) has a current PS of 14.70. The 5-year average PS is 19.44. The thresholds are as follows: Strongly Undervalued below -19.75, Undervalued between -19.75 and -0.15, Fairly Valued between 39.04 and -0.15, Overvalued between 39.04 and 58.63, and Strongly Overvalued above 58.63. The current Forward PS of 14.70 falls within the Historic Trend Line -Fairly Valued range.
-0.66
P/OCF
TScan Therapeutics Inc. (TCRX) has a current P/OCF of -0.66. The 5-year average P/OCF is -1.48. The thresholds are as follows: Strongly Undervalued below -5.15, Undervalued between -5.15 and -3.32, Fairly Valued between 0.36 and -3.32, Overvalued between 0.36 and 2.19, and Strongly Overvalued above 2.19. The current Forward P/OCF of -0.66 falls within the Historic Trend Line -Fairly Valued range.
-0.70
P/FCF
TScan Therapeutics Inc. (TCRX) has a current P/FCF of -0.70. The 5-year average P/FCF is -1.91. The thresholds are as follows: Strongly Undervalued below -4.36, Undervalued between -4.36 and -3.13, Fairly Valued between -0.68 and -3.13, Overvalued between -0.68 and 0.55, and Strongly Overvalued above 0.55. The current Forward P/FCF of -0.70 falls within the Historic Trend Line -Fairly Valued range.
TScan Therapeutics Inc (TCRX) has a current Price-to-Book (P/B) ratio of 0.54. Compared to its 3-year average P/B ratio of 1.05 , the current P/B ratio is approximately -48.70% higher. Relative to its 5-year average P/B ratio of 0.91, the current P/B ratio is about -40.58% higher. TScan Therapeutics Inc (TCRX) has a Forward Free Cash Flow (FCF) yield of approximately -129.21%. Compared to its 3-year average FCF yield of -76.05%, the current FCF yield is approximately 69.90% lower. Relative to its 5-year average FCF yield of -71.15% , the current FCF yield is about 81.59% lower.
0.55
P/B
Median3y
1.05
Median5y
0.91
-137.67
FCF Yield
Median3y
-76.05
Median5y
-71.15
Competitors Valuation Multiple
The average P/S ratio for TCRX's competitors is 51.41, providing a benchmark for relative valuation. TScan Therapeutics Inc Corp (TCRX) exhibits a P/S ratio of 14.70, which is -71.40% above the industry average. Given its robust revenue growth of 473.88%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TCRX decreased by 69.09% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 536.00K to 3.08M.
The secondary factor is the Margin Expansion, contributed -79.66%to the performance.
Overall, the performance of TCRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
CSBR
Champions Oncology Inc
7.410
USD
+1.23%
FGBI
First Guaranty Bancshares Inc
7.700
USD
-4.11%
LTRX
Lantronix Inc
3.440
USD
+6.50%
CMT
Core Molding Technologies Inc
18.340
USD
+1.27%
SBFG
SB Financial Group Inc
20.700
USD
-0.24%
XNET
Xunlei Ltd
7.250
USD
-0.96%
LCUT
Lifetime Brands Inc
3.810
USD
+1.06%
SEER
Seer Inc
2.050
USD
0.00%
LFT
Lument Finance Trust Inc
2.140
USD
-1.83%
FAQ
Is TScan Therapeutics Inc (TCRX) currently overvalued or undervalued?
TScan Therapeutics Inc (TCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 15.66 is considered Undervalued compared with the five-year average of -2.57. The fair price of TScan Therapeutics Inc (TCRX) is between 2.52 to 5.03 according to relative valuation methord. Compared to the current price of 1.70 USD , TScan Therapeutics Inc is Undervalued By 32.59% .
What is TScan Therapeutics Inc (TCRX) fair value?
How does TCRX's valuation metrics compare to the industry average?
What is the current P/B ratio for TScan Therapeutics Inc (TCRX) as of Aug 22 2025?
What is the current FCF Yield for TScan Therapeutics Inc (TCRX) as of Aug 22 2025?
What is the current Forward P/E ratio for TScan Therapeutics Inc (TCRX) as of Aug 22 2025?